<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01332448</url>
  </required_header>
  <id_info>
    <org_study_id>114237</org_study_id>
    <nct_id>NCT01332448</nct_id>
  </id_info>
  <brief_title>Meta-analysis of Orlistat Laboratory Data From Placebo-controlled Clinical Trials</brief_title>
  <official_title>Meta-analysis of Orlistat Laboratory Data From Placebo-controlled Clinical Trials</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Roche and GSK will carry out a meta-analysis of liver function data from trials of orlistat
      to establish whether there is any indication of liver toxicity. The motivation is a
      cumulative assessment of drug-induced liver injury (DILI) conducted by the FDA following
      spontaneous reports of liver toxicity in people taking Xenical or Alli.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Odds ratio (Orlistat120:Placebo) for subjects experiencing alanine transaminase (ALT) greater than upper limit of normal (ULN)</measure>
    <time_frame>within one year of starting treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Odds ratio (Orlistat120:Placebo) for subjects experiencing total bilirubin (BIL) &gt; ULN</measure>
    <time_frame>within one year of starting treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Odds ratio (Orlistat120:Placebo) for subjects experiencing ALT &gt; ULN for successive measurements more than two weeks apart</measure>
    <time_frame>within one year of starting treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Odds ratio (Orlistat120:Placebo) for subjects experiencing BIL &gt; ULN for successive measurements greater than two weeks apart</measure>
    <time_frame>within one year of starting treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Odds ratio (Orlistat60:Placebo) for subjects experiencing ALT &gt; ULN</measure>
    <time_frame>within one year of starting treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Odds ratio (Orlistat60:Placebo) for subjects experiencing BIL &gt; ULN</measure>
    <time_frame>within one year of starting treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Odds ratio (Orlistat60:Placebo) for subjects experiencing ALT &gt; ULN for successive measurements more than two weeks apart</measure>
    <time_frame>within one year of starting treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Odds ratio (Orlistat60:Placebo) for subjects experiencing BIL &gt; ULN for successive measurements greater than two weeks apart</measure>
    <time_frame>within one year of starting treatment</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">1</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Orlistat 120</arm_group_label>
    <description>Orlistat 120mg tid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orlistat 60</arm_group_label>
    <description>Orlistat 60 mg tid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <description>No active drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orlistat 120</intervention_name>
    <description>Orlistat 120mg tid</description>
    <arm_group_label>Orlistat 120</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orlistat 60</intervention_name>
    <description>Orlistat 60mg tid</description>
    <arm_group_label>Orlistat 60</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All clinical trials found by search procedure:

          1. In-house trial repositories at GSK and Roche

          2. EMBASE (which includes MEDLINE) using the terms &quot;orlistat&quot;, &quot;Xenical&quot; or &quot;Alli&quot;, with
             &quot;placebo&quot; and &quot;clinical trial&quot;

          3. Recently published meta-analyses found by the search will also be searched for
             relevant trials
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The trial must be randomized and placebo-controlled

          2. The orlistat dose must be 60mg or 120mg

          3. Data on ALT or BIL must be available

          4. The nominal treatment period must be 16 weeks or longer

        Exclusion Criteria:

        1. If cross-over trials are found, data from other than the first period will be excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2011</study_first_submitted>
  <study_first_submitted_qc>April 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2011</study_first_posted>
  <last_update_submitted>June 1, 2017</last_update_submitted>
  <last_update_submitted_qc>June 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Xenical</keyword>
  <keyword>Alli</keyword>
  <keyword>safety</keyword>
  <keyword>meta-analysis</keyword>
  <keyword>liver-function test</keyword>
  <keyword>Roche</keyword>
  <keyword>orlistat</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Orlistat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

